APYX

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Apyx Medical (APYX – Research Report), with a price target of $11.00. The company's shares closed last Monday at $8.09. According to TipRanks.com, Turkaly is a 3-star analyst with an average return of 2.5% and a 42.4% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics. Apyx Medical has an analyst consensus of Strong Buy, with a price target consensus of $12.50, which is a 53.9% upside from current levels.
https://www.tipranks.com/news/blurbs/apyx-medical-apyx-receives-a-buy-from-jmp-securities?utm_source=advfn.com&utm_medium=referral